Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Average Rating of “Buy” by Analysts

Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) have been given a consensus recommendation of “Buy” by the twelve research firms that are presently covering the company, MarketBeat reports. Ten equities research analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $56.27.

Several research firms have recently issued reports on MIRM. JPMorgan Chase & Co. raised their price objective on Mirum Pharmaceuticals from $31.00 to $39.00 and gave the company an “overweight” rating in a research note on Tuesday, June 18th. HC Wainwright reaffirmed a “buy” rating and set a $66.00 price objective on shares of Mirum Pharmaceuticals in a research note on Friday, July 26th. Morgan Stanley increased their target price on shares of Mirum Pharmaceuticals from $53.00 to $57.00 and gave the company an “overweight” rating in a research note on Tuesday, June 18th. Robert W. Baird raised their target price on shares of Mirum Pharmaceuticals from $39.00 to $44.00 and gave the stock an “outperform” rating in a report on Thursday, August 8th. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $48.00 price target on shares of Mirum Pharmaceuticals in a report on Monday, June 17th.

Mirum Pharmaceuticals Trading Down 1.9 %

MIRM stock opened at $41.13 on Friday. The firm has a fifty day moving average price of $40.46 and a 200 day moving average price of $31.57. Mirum Pharmaceuticals has a fifty-two week low of $23.14 and a fifty-two week high of $45.23. The firm has a market cap of $1.94 billion, a PE ratio of -11.09 and a beta of 1.14. The company has a debt-to-equity ratio of 1.34, a quick ratio of 3.09 and a current ratio of 3.28.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.05). The business had revenue of $77.90 million during the quarter, compared to analysts’ expectations of $75.03 million. Mirum Pharmaceuticals had a negative return on equity of 43.47% and a negative net margin of 40.34%. The business’s quarterly revenue was up 107.7% on a year-over-year basis. During the same period in the previous year, the business earned ($0.92) earnings per share. Sell-side analysts anticipate that Mirum Pharmaceuticals will post -1.75 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Mirum Pharmaceuticals news, insider Pamela Vig sold 30,559 shares of Mirum Pharmaceuticals stock in a transaction on Monday, June 24th. The stock was sold at an average price of $34.00, for a total transaction of $1,039,006.00. Following the completion of the sale, the insider now directly owns 27,406 shares of the company’s stock, valued at approximately $931,804. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 22.87% of the stock is owned by insiders.

Institutional Trading of Mirum Pharmaceuticals

A number of hedge funds have recently bought and sold shares of MIRM. Victory Capital Management Inc. purchased a new stake in Mirum Pharmaceuticals during the fourth quarter worth $594,000. Swiss National Bank lifted its holdings in Mirum Pharmaceuticals by 9.0% during the fourth quarter. Swiss National Bank now owns 59,300 shares of the company’s stock worth $1,751,000 after buying an additional 4,900 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in Mirum Pharmaceuticals by 18.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 266,681 shares of the company’s stock worth $7,872,000 after buying an additional 42,110 shares during the period. Teacher Retirement System of Texas lifted its holdings in Mirum Pharmaceuticals by 1,858.5% during the fourth quarter. Teacher Retirement System of Texas now owns 137,216 shares of the company’s stock worth $4,051,000 after buying an additional 130,210 shares during the period. Finally, First Turn Management LLC purchased a new stake in Mirum Pharmaceuticals during the fourth quarter worth $24,688,000.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.